However, recent meta-analyses on randomized control trials have negated any significant difference with regard to malignancies (all types) or bladder cancer (specifically) in patients treated with SGLT2 inhibitors compared to other hypoglycemic agents or placebos. Here, SLC5A2 is linked to urinary bladder carcinoma.